Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

Rajani Ravi, Kimberly Noonan, Vui Pham, Rishi Bedi, Alex Zhavoronkov, Ivan V. Ozerov, Eugene Makarev, Artem V. Artemov, Piotr T. Wysocki, Ranee Mehra, Sridhar Nimmagadda, Luigi Marchionni, David Sidransky, Ivan M Borrello, Evgeny Izumchenko, Atul Bedi

Research output: Contribution to journalArticle

Abstract

A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)/PD-1 ligand (PD-L1). Cancers frequently express transforming growth factor-β (TGFβ), which drives immune dysfunction in the tumor microenvironment by inducing regulatory T cells (Tregs) and inhibiting CD8+ and TH1 cells. To address this therapeutic challenge, we invent bifunctional antibody-ligand traps (Y-traps) comprising an antibody targeting CTLA-4 or PD-L1 fused to a TGFβ receptor II ectodomain sequence that simultaneously disables autocrine/paracrine TGFβ in the target cell microenvironment (a-CTLA4-TGFβRIIecd and a-PDL1-TGFβRIIecd). a-CTLA4-TGFβRIIecd is more effective in reducing tumor-infiltrating Tregs and inhibiting tumor progression compared with CTLA-4 antibody (Ipilimumab). Likewise, a-PDL1-TGFβRIIecd exhibits superior antitumor efficacy compared with PD-L1 antibodies (Atezolizumab or Avelumab). Our data demonstrate that Y-traps counteract TGFβ-mediated differentiation of Tregs and immune tolerance, thereby providing a potentially more effective immunotherapeutic strategy against cancers that are resistant to current immune checkpoint inhibitors.

Original languageEnglish (US)
Article number741
JournalNature Communications
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Transforming Growth Factors
CTLA-4 Antigen
antibodies
Immunotherapy
cancer
traps
Ligands
lymphocytes
Tumors
antigens
ligands
Antibodies
tumors
Neoplasms
death
Bispecific Antibodies
T-cells
Growth Factor Receptors
Cellular Microenvironment
Immune Tolerance

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. / Ravi, Rajani; Noonan, Kimberly; Pham, Vui; Bedi, Rishi; Zhavoronkov, Alex; Ozerov, Ivan V.; Makarev, Eugene; Artemov, Artem V.; Wysocki, Piotr T.; Mehra, Ranee; Nimmagadda, Sridhar; Marchionni, Luigi; Sidransky, David; Borrello, Ivan M; Izumchenko, Evgeny; Bedi, Atul.

In: Nature Communications, Vol. 9, No. 1, 741, 01.12.2018.

Research output: Contribution to journalArticle

Ravi, Rajani ; Noonan, Kimberly ; Pham, Vui ; Bedi, Rishi ; Zhavoronkov, Alex ; Ozerov, Ivan V. ; Makarev, Eugene ; Artemov, Artem V. ; Wysocki, Piotr T. ; Mehra, Ranee ; Nimmagadda, Sridhar ; Marchionni, Luigi ; Sidransky, David ; Borrello, Ivan M ; Izumchenko, Evgeny ; Bedi, Atul. / Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. In: Nature Communications. 2018 ; Vol. 9, No. 1.
@article{1c07c11b51424f1ab7c9063729ab6ff7,
title = "Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy",
abstract = "A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)/PD-1 ligand (PD-L1). Cancers frequently express transforming growth factor-β (TGFβ), which drives immune dysfunction in the tumor microenvironment by inducing regulatory T cells (Tregs) and inhibiting CD8+ and TH1 cells. To address this therapeutic challenge, we invent bifunctional antibody-ligand traps (Y-traps) comprising an antibody targeting CTLA-4 or PD-L1 fused to a TGFβ receptor II ectodomain sequence that simultaneously disables autocrine/paracrine TGFβ in the target cell microenvironment (a-CTLA4-TGFβRIIecd and a-PDL1-TGFβRIIecd). a-CTLA4-TGFβRIIecd is more effective in reducing tumor-infiltrating Tregs and inhibiting tumor progression compared with CTLA-4 antibody (Ipilimumab). Likewise, a-PDL1-TGFβRIIecd exhibits superior antitumor efficacy compared with PD-L1 antibodies (Atezolizumab or Avelumab). Our data demonstrate that Y-traps counteract TGFβ-mediated differentiation of Tregs and immune tolerance, thereby providing a potentially more effective immunotherapeutic strategy against cancers that are resistant to current immune checkpoint inhibitors.",
author = "Rajani Ravi and Kimberly Noonan and Vui Pham and Rishi Bedi and Alex Zhavoronkov and Ozerov, {Ivan V.} and Eugene Makarev and Artemov, {Artem V.} and Wysocki, {Piotr T.} and Ranee Mehra and Sridhar Nimmagadda and Luigi Marchionni and David Sidransky and Borrello, {Ivan M} and Evgeny Izumchenko and Atul Bedi",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-017-02696-6",
language = "English (US)",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

AU - Ravi, Rajani

AU - Noonan, Kimberly

AU - Pham, Vui

AU - Bedi, Rishi

AU - Zhavoronkov, Alex

AU - Ozerov, Ivan V.

AU - Makarev, Eugene

AU - Artemov, Artem V.

AU - Wysocki, Piotr T.

AU - Mehra, Ranee

AU - Nimmagadda, Sridhar

AU - Marchionni, Luigi

AU - Sidransky, David

AU - Borrello, Ivan M

AU - Izumchenko, Evgeny

AU - Bedi, Atul

PY - 2018/12/1

Y1 - 2018/12/1

N2 - A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)/PD-1 ligand (PD-L1). Cancers frequently express transforming growth factor-β (TGFβ), which drives immune dysfunction in the tumor microenvironment by inducing regulatory T cells (Tregs) and inhibiting CD8+ and TH1 cells. To address this therapeutic challenge, we invent bifunctional antibody-ligand traps (Y-traps) comprising an antibody targeting CTLA-4 or PD-L1 fused to a TGFβ receptor II ectodomain sequence that simultaneously disables autocrine/paracrine TGFβ in the target cell microenvironment (a-CTLA4-TGFβRIIecd and a-PDL1-TGFβRIIecd). a-CTLA4-TGFβRIIecd is more effective in reducing tumor-infiltrating Tregs and inhibiting tumor progression compared with CTLA-4 antibody (Ipilimumab). Likewise, a-PDL1-TGFβRIIecd exhibits superior antitumor efficacy compared with PD-L1 antibodies (Atezolizumab or Avelumab). Our data demonstrate that Y-traps counteract TGFβ-mediated differentiation of Tregs and immune tolerance, thereby providing a potentially more effective immunotherapeutic strategy against cancers that are resistant to current immune checkpoint inhibitors.

AB - A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)/PD-1 ligand (PD-L1). Cancers frequently express transforming growth factor-β (TGFβ), which drives immune dysfunction in the tumor microenvironment by inducing regulatory T cells (Tregs) and inhibiting CD8+ and TH1 cells. To address this therapeutic challenge, we invent bifunctional antibody-ligand traps (Y-traps) comprising an antibody targeting CTLA-4 or PD-L1 fused to a TGFβ receptor II ectodomain sequence that simultaneously disables autocrine/paracrine TGFβ in the target cell microenvironment (a-CTLA4-TGFβRIIecd and a-PDL1-TGFβRIIecd). a-CTLA4-TGFβRIIecd is more effective in reducing tumor-infiltrating Tregs and inhibiting tumor progression compared with CTLA-4 antibody (Ipilimumab). Likewise, a-PDL1-TGFβRIIecd exhibits superior antitumor efficacy compared with PD-L1 antibodies (Atezolizumab or Avelumab). Our data demonstrate that Y-traps counteract TGFβ-mediated differentiation of Tregs and immune tolerance, thereby providing a potentially more effective immunotherapeutic strategy against cancers that are resistant to current immune checkpoint inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85042362546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042362546&partnerID=8YFLogxK

U2 - 10.1038/s41467-017-02696-6

DO - 10.1038/s41467-017-02696-6

M3 - Article

C2 - 29467463

AN - SCOPUS:85042362546

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 741

ER -